AGEs-RAGE系统与二甲双胍抗肿瘤作用研究进展

AGEs-RAGE system and anti-tumor effect of metformin

二甲双胍可明显降低糖尿病人群肿瘤的发生率和死亡率,特别可降低糖尿病人患结肠癌、肝癌、肺癌风险,有报道示晚期糖基化终产物(advanced glycation end products,AGEs)通过与其受体(receptor for advanced glycation end products,RAGE)相互作用能刺激肾癌、胰腺癌、黑色素瘤、结肠癌、肝癌细胞的生长和/或迁移。然而二甲双胍对恶性肿瘤细胞AGEs-RAGE轴的作用尚不清楚。有研究者认为AGEs-RAGE系统可能是二甲双胍抗肿瘤的重要途径。本文就AGEs-RAGE系统探讨二甲双胍的抗肿瘤作用机制做一综述。

Metformin has been reported to decrease cancer incidence and mortality in diabetic patients. It has also been reported that advanced glycation end products （AGEs） and their receptor （RAGE） interaction stimulate growth and/or migration of kidney neoplasm, pancreatic cancer, melanoma ceils, colorectal neoplasm, and liver neoplasm. However, effects of metformin on AGEs-RAGE axis in cancers remain unknown. It has been indicated that AGEs-RAGE system may be an important way by which metformin confront cancer. In this paper, we reviewed research progress in AGEs-RAGE system and anti-tumor effect of metformin.